Skip to main content

Table 1 Correlation of miR-126 expression with clinicopathological features of PCa patients

From: Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy

Clinicopathological features

Cases No (n, %)

miR-126 expression status

P

Low (n, %)

High (n, %)

Age

    

<70

70 (54.69)

39 (55.71)

31 (44.29)

NS

≥70

58 (45.31)

29 (50.00)

29 (50.00)

Preoperative PSA

    

<4 ng/mL

3 (2.34)

0 (0)

3 (100.00)

0.003

4-10 ng/mL

35 (27.34)

7 (20.00)

28 (80.00)

>10 ng/mL

90 (70.31)

61 (67.77)

29 (32.23)

 

Gleason score

    

4-6

62 (48.44)

31 (50.00)

31 (50.00)

NS

7

30 (23.44)

19 (63.33)

11 (36.67)

8-10

36 (28.13)

18 (50.00)

18 (50.00)

 

Pathological stage

    

T1

72 (56.25)

22 (30.56)

50 (69.44)

0.001

T2/T3

56 (43.75)

46 (82.14)

10 (17.86)

Lymph node metastasis

    

Negative

106 (82.81)

47 (44.34)

59 (55.66)

0.006

Positive

22 (17.19)

21 (95.45)

1 (4.55)

Angiolymphatic invasion

    

Negative

110 (85.94)

50 (45.45)

60 (54.55)

0.001

Positive

18 (14.06)

18 (100.00)

0 (0)

Surgical margin status

    

Negative

108 (84.38)

56 (51.85)

52 (48.15)

NS

Positive

20 (15.62)

12 (60.00)

8 (40.00)

 
  1. Note: ‘NS’ refers to the difference without statistic significance.